Status:
COMPLETED
Dextenza in Pterygium Surgery
Lead Sponsor:
Michelle Rhee MD
Collaborating Sponsors:
Ocular Therapeutix, Inc.
Conditions:
Pterygium
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
DEXTENZA for the treatment of post-surgical pain and inflammation compared to standard of care topical prednisolone acetate 1% in patients who undergo pterygium surgery (excision of pterygium with con...
Detailed Description
In patients who undergo pterygium surgery, eyes will be consecutively assigned to receive either DEXTENZA or topical prednisolone acetate 1%.15 eyes will receive a Dextenza insertion into both the upp...
Eligibility Criteria
Inclusion
- A patient's study eye must meet the following criteria to be eligible for inclusion in the study:
- • Age of at least 18 years with primary pterygia
Exclusion
- A patient who meets any of the following criteria will be excluded from the study:
- Glaucoma
- Ocular hypertension
- Prior conjunctival surgery
- Other uncontrolled ocular disease
- Ocular surgery in either eye within 3 months
- Use of eye drops other than postoperative medications and artificial tears
Key Trial Info
Start Date :
October 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 5 2021
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04403516
Start Date
October 1 2020
End Date
August 5 2021
Last Update
April 6 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New York Eye Specialists
New York, New York, United States, 10016